Related Experiment Video

Updated: Jun 30, 2026

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

Latest Management of Cardiac Sarcoidosis: A Comprehensive Review

Dunia Alhareth1, Alaaeddine El Ghazawi1, Sara Ajami2

  • 1Department of Internal Medicine, Cardiology Division, American University of Beirut Medical Center, Beirut, Lebanon, aubmc.org.lb.

Cardiology Research and Practice
|June 29, 2026
PubMed

Insights

Cardiac sarcoidosis (CS) management involves medications, devices, and lifestyle changes. Corticosteroids help inflammation, but steroid-sparing drugs are alternatives. Device interventions and ablation address arrhythmias and heart failure in CS.

Area of Science:

  • Cardiology
  • Immunology
  • Internal Medicine

Background:

  • Cardiac sarcoidosis (CS) is a rare, serious manifestation of sarcoidosis.
  • CS presents heterogeneously, complicating diagnosis and management.
  • Potential complications include conduction blocks, arrhythmias, and heart failure.

Purpose of the Study:

  • To review management options for cardiac sarcoidosis.
  • To discuss pharmacotherapy, device-based interventions, lifestyle modifications, and surgical options for CS.
  • To highlight challenges in CS treatment, including interindividual variability and lack of strict guidelines.

Main Methods:

  • Literature review of CS management strategies.
  • Analysis of pharmacotherapy, including corticosteroids and steroid-sparing agents.
  • Evaluation of device-based interventions (pacemakers, ICDs) and ablation techniques.
  • Consideration of lifestyle modifications and surgical approaches.

Main Results:

  • Corticosteroids show efficacy in reducing CS inflammation and improving cardiac parameters.
  • Steroid-sparing medications are viable alternatives due to corticosteroid side effects.
  • Device interventions and ablation are effective for managing arrhythmias and heart failure in CS patients.
  • Lifestyle modifications are important adjunctive treatments.

Conclusions:

  • Cardiac sarcoidosis requires a multifaceted management approach.
  • Treatment strategies must balance efficacy with potential side effects and patient variability.
  • Further research is needed to establish standardized guidelines for CS management.

Keywords:
cardiac sarcoidosisdevice-based interventionslifestyle modificationspharmacological treatment

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...